Phenotypical analysis in a group of endometriosis-associated ovarian cancers revealed aberrant expression of KIT and downregulation of ARID1A.[16] Therefore, it is likely to assume that both Arid1a and Kit mutations contribute to myeloid sarcoma co-occurring mastocytosis in our patient. Here, ARID1A is linked to ovarian carcinoma.